GC Cell Corporation (KOSDAQ:144510)

Market Cap	301.29B
Revenue (ttm)	174.45B
Net Income (ttm)	-73.90B
Shares Out	15.03M
EPS (ttm)	-4,918.00
PE Ratio	n/a
Forward PE	n/a
Dividend	100.00 (0.50%)
Ex-Dividend Date	n/a

Volume	2,171
Average Volume	25,603
Open	20,050
Previous Close	20,050
Day's Range	19,910 - 20,250
52-Week Range	16,940 - 38,000
Beta	1.32
RSI	43.09
Earnings Date	May 9, 2025

About GC Cell

GC Cell Corporation develops cell therapy products. It also provides cell banking, sample inspection, clinical trial, and bio logistics services. Its main product is Immuncell-LC. GC Cell Corporation has strategic agreement with Lukas Biomedical Co., Ltd. to develop Cell therapy. The company was formerly known as Green Cross Lab Cell Corporation and changed its name to GC Cell Corporation in November 2021. GC Cell Corporation was founded in 2011 and is based in Yongin-si, South Korea.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2011
• Employees: 752
• Stock Exchange: KOSDAQ
• Ticker Symbol: 144510

Financial Performance

In 2024, GC Cell's revenue was 174.45 billion, a decrease of -6.98% compared to the previous year's 187.54 billion. Losses were -73.90 billion, 42368.9% more than in 2023.